Skip to content

Functional Brands, Inc. MEHA Common stock issuance for private placement

Common stock issuance for private placement at other companies

Beta Bionics, Inc. Common Stock logo
Beta Bionics, Inc. Common StockBBNX
$15.59M
Eton Pharmaceuticals, Inc. logo
Eton Pharmaceuticals, Inc.ETON
$0-100%
Vor Biopharma logo
Vor BiopharmaVOR
$75M
Climb Bio, Inc. logo
Climb Bio, Inc.CLYM
$0-100%
CleanSpark logo
CleanSparkCLSK
$0-100%
Archer Aviation logo
Archer AviationACHR
$0-100%

Other financials

Income statement

See full
Revenue$1.6M+3.5%
Gross profit$961.1K+10.9%
Operating income-$682.8K-2,027%
Net income-$7.0M-5,414%
EPS (diluted)-$0.36-1,700%

Balance sheet

See full
Cash & equivalents$1.1M+401%
Total debt$2.0M
Total equity-$4.5M-3,048%
Total assets$7.2M

Cash flow

See full
Operating cash flow-$424.6K-341%
CapEx$1.0-99.8%
Free cash flow-$2.7M-4,996%

Valuation

See full
Market cap$793.48K-92.8%
Enterprise value$1.72M
P/S0.1×

Profitability

See full
Gross margin53.7%
Operating margin-30.7%
Net margin-90.1%

Returns & leverage

See full
Return on equity275.7%
Debt / equity1.4×
Current ratio1.2×

Where this comes from

Reported directly by Functional Brands, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfPrivatePlacement.

The official record: Functional Brands, Inc. ’s 10-K, filed March 27, 2026, on SEC EDGAR. View the filing →

Ask your AI about Functional Brands, Inc. 's common stock issuance for private placement.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Functional Brands, Inc. 's common stock issuance for private placement?
Functional Brands, Inc. (MEHA) reported common stock issuance for private placement of $8M in Q4 2025.
What does common stock issuance for private placement mean?
The total cash proceeds received by the company from the sale of equity or debt securities directly to private investors rather than through a public offering. This is a critical liquidity metric for clinical-stage companies that rely on private capital to fund research and development. It highlights the company's ability to secure non-dilutive or private funding to sustain operations.